Biomarker Research · Nov 18, 2026

Circulating biomarkers in early-stage hepatocellular carcinoma for risk stratification, diagnosis and prognosis

By Monti E, Bella M, Vianello C et al.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, largely due to tumor heterogeneity, late diagnosis, and high recurrence rates even after curative treatment. Although HCC is potentially curable when detected at an early stage, suboptimal surveillance, particularly in patients with underlying cirrhosis or metabolic risk factors, limits the proportion of patients eligible for curative therapies. Current surveillance strategies for at-risk populations have intrinsic limitations, and the performance of imaging and serum biomarkers remains suboptimal. Moreover, the lack of reliable prognostic biomarkers for detecting early recurrence hampers post-treatment surveillance and impacts clinical outcomes. In this context, circulating biomarkers have emerged as promising tools for improving both early detection and prognostic stratification. Liquid biopsy has the potential to enable early, non-invasive diagnosis of HCC and allows longitudinal assessment of tumor progression through serial sampling. In early-stage HCC, blood candidates may complement or outperform conventional approaches by enabling earlier diagnosis and more accurate risk stratification. In this review, we summarize recent advances and current challenges in the clinical translation of circulating biomarkers. We focus on key liquid biopsy components, including circulating cell-free DNA, particularly circulating tumor DNA, circulating tumor cells, non-coding RNAs, extracellular vesicles, proteins and metabolites, such as bile acids and lipids, highlighting their diagnostic and prognostic potential and their possible integration into personalized management strategies for patients with early-stage HCC.

doi.org/10.1186/s40364-026-01045-4Open accessPubMed 43053253Biomarkers

AgingResearch.News